Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 264

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 264
---
 the election of the new members to the NLS Board. •Proposal No. 13 to approve the CVR Agreement. •Proposal No. 14 to approve the conversion of outstanding options and RSUs issued by Kadimastem. Further agenda items are: •Proposal No. 3 to approve the ordinary share capital increase regarding the issuance of NLS Preferred Shares. •Proposal No. 5 to approve the conditional share capital for employee and advisory options. •Proposal No. 7 to approve the transfer and voting rights limitation of 9.99%. •Proposal No. 8 to approve the name change of NLS. •Proposal No. 10 to approve the election of members of the Compensation, Nomination and Governance Committee. •Proposal No. 11 to approve the composition of the new senior management following the Merger. •Proposal No. 12.1 to approve the compensation for the members of the NLS Board. •Proposal No. 12.2 to approve the compensation for the executive officers. Recommendation of the NLS Board The NLS Board has unanimously determined that the each of the Proposals is fair to and in the best interests of NLS and its shareholders; has unanimously approved each of the Proposals; and unanimously recommends that shareholders vote “FOR” each of the Proposals. 104 Record Date; Outstanding Shares; Shareholders Entitled to Vote As of August28, 2025, NLS has a share capital of CHF 178,738.14 divided into 4,908,034 NLS Common Shares, and 1,249,904 NLS Preferred Shares, par value of CHF 0.03 each per the Commercial Register of Zurich under Swiss Law. Additionally, as of August28, 2025, NLS has issued 606,452 Preferred Participation Certificates as of the date of this proxy statement/prospectus. Of the aforementioned number of shares, as of August28, 2025, NLS holds 655,977 NLS Common Shares and 23,254 Preferred Participation Certificates held in the Company’s treasury are considered treasury shares per Swiss corporate law, which are therefore not entitled to a vote at the NLS Meeting. For more information about treasury shares under Swiss law, please see “ Comparison of Shareholders’ Rights and Corporate Governance — Summary of Material Differences Between the Rights of Kadimastem Shareholders and NL Shareholders — Rights of NLS Pharmaceutics shareholders — Treasury Shares.” The aforementioned treasury shares have never been issued